Investing Ideas
/
Global Pharmaceuticals & Biotech Inefficient Market Opportunities

Global Pharmaceuticals & Biotech Inefficient Market Opportunities

Results

0 new

Less coverage brings about more information asymmetry and more opportunities to buy mispriced stocks. Companies valued at less than US$500M with low PE and PEG.

1 companies

Protalix BioTherapeutics

Market Cap: US$132.9m

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.

PLX

US$1.68

15.1%

40.0%